Automated Healthcare: ChatGPT, Bing, Bard & the Law of Generative AI

---

LIVEWEBINARDHPAMA

Saturday, June 17, 2023, 3:00 PM - 6:15 PM, Livestreamed (via Zoom)

ChatGPT has gained global and systemic attention in 2023. It is the largest language model ever built, using deep learning to produce human-like text. Its potential uses are far-ranging, such as generating human-like conversations, content creation, writing code, and much more. Many sectors will be impacted from marketing, education, entertainment, finance, and healthcare. In healthcare, the potential uses may have global ramifications. Sophisticated generative AI systems could revolutionise virtual assistants and their interactions with patients. They could be used as a clinical decision support, for medical recordkeeping, medical translation, patient triage, mental health support, remote patient monitoring, among others. While these applications may be beneficial, they also raise risks for end users, and raise questions about the ownership of information. At the same time, there is no overarching legislative framework governing this space. Discussions are needed about harnessing the benefits of this technology while ensuring legal clarity surrounding medical liability, informed consent, and privacy. There are important questions about what guidelines should require at the development stage of generative AI so that biases are minimised in the data used to train these systems. There is also uncertainty about who owns the information generated from chatbots in the healthcare context. Detailed discussions between experts in the field can help to illuminate the path forward.

1. 1- Outline the uses of generative AI in healthcare.
2. 2- Identify ethical and legal challenges of using generative AI in healthcare.
3. 3- Appraise the limitations of the laws regulating generative AI.

No registration fees.

The registration closes ONE day before the activity. You will receive a UNIQUE link to join the webinar on the day of the presentation.

DHP 

Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Ministry of Public Health's Department of Healthcare Professions.

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Ministry of Public Health's Department of Healthcare Professions-Accreditation Section and is approved for a maximum of 3.00 hours.

ACCME

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Weill Cornell Medicine-Qatar and Hamad Bin Khalifa University.

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Relationships/Content Validity

It is the policy of Weill Cornell Medicine-Qatar to adhere to the Department of Healthcare Professions (DHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias. 

Course Directors: Thurayya Arayssi, MD, Barry Solaiman, PhD, have no relevant financial relationships to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

Scientific Planning Committee: Thurayya Arayssi, MD, Barry Solaiman, PhD, Deema Al-Sheikhly, MRes, MEHP, Phyllis Sui Muffuh Navti, Doctorate in Pharmacy Practice, Michael Saretsky, PT, Konstantinos  Epameinontidis, PT, Nelly Khalil, MPH, Constantina Dalassou, DDS, have no relevant financial relationships to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

Faculty: Thurayya Arayssi, MD, Barry Solaiman, PhD, Faisal Farooq, PhD, Jessica Roberts, JD, Alaa Abd-alrazaq, PhD, Arfan Ahmed, PhD, have no relevant financial relationships to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

Sara Gerke, JD, has disclosed the following financial relationships: Grant or research support - European Union | Grant or research support - National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health | Grant or research support-Rock Ethics Institute at Penn State University | Honoraria - WCG IRB. The financial relationships are not relevant; WILL NOT BE DISCUSSING unalabeled/unapproved use of drugs or products.

David Simon, PhD, has disclosed the following financial relationships: Grant or research support - Gordon and Betty More Foundation | Ownership - Simon Law Group LLC. The financial relationships are not relevant; WILL NOT BE DISCUSSING unalabeled/unapproved use of drugs or products.

Jamie Gray, MLS, has disclosed the following financial relationships: Stocks or stock options, excluding diversified mutual funds - Colgate-Palmolive | Stocks or stock options, excluding diversified mutual funds - Proctor & Gamble. The financial relationships are not relevant; WILL NOT BE DISCUSSING unalabeled/unapproved use of drugs or products.

 Administrative Contact: Safia Rabia has no relevant financial relationships to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

ICR: Barry Solaiman, PhD, has no relevant financial relationships to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.

Mitigation of Relevant Financial Relationships

Weill Cornell Medicine-Qatar adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Saturday, June 17, 2023